Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$80 Mln
P/E Ratio
--
P/B Ratio
2.2
Industry P/E
--
Debt to Equity
0.05
ROE
-0.85 %
ROCE
3.94 %
Div. Yield
0 %
Book Value
0.75
EPS
0.03
CFO
$-118.21 Mln
EBITDA
$-132.55 Mln
Net Profit
$-138.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
InspireMD (NSPR)
| -8.09 | -10.47 | -5.20 | 20.87 | -1.77 | -26.32 | -72.56 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
InspireMD (NSPR)
| -6.36 | 226.93 | -71.52 | -40.78 | -68.52 | -86.50 | 22.94 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 12.68 | 10,562.04 | 12.43 | 12.69 | |
| 72.59 | 10,050.19 | 97.07 | 2.52 | |
| 163.46 | 8,847.72 | -- | -25.23 | |
| 298.21 | 11,609.25 | 277.57 | 3.65 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company... offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida. Address: 6303 Waterford District Drive, Miami, FL, United States, 33126 Read more
President, CEO & Director
Mr. Marvin L. Slosman
President, CEO & Director
Mr. Marvin L. Slosman
Headquarters
Miami, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of InspireMD Inc (NSPR) stood at $ 47 Mln as on 31-Dec-24
The share price of InspireMD Inc (NSPR) is $2.42 (NASDAQ) as of 29-Apr-2025 15:38 EDT. InspireMD Inc (NSPR) has given a return of -1.77% in the last 3 years.
InspireMD Inc (NSPR) has a market capitalisation of $ 80 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of InspireMD Inc (NSPR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the InspireMD Inc (NSPR) and enter the required number of quantities and click on buy to purchase the shares of InspireMD Inc (NSPR).
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida. Address: 6303 Waterford District Drive, Miami, FL, United States, 33126
The CEO & director of Mr. Marvin L. Slosman. is InspireMD Inc (NSPR), and CFO & Sr. VP is Mr. Marvin L. Slosman.
There is no promoter pledging in InspireMD Inc (NSPR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,078
|
|
|
1,054
|
|
|
964
|
|
|
853
|
| InspireMD Inc. (NSPR) | Ratios |
|---|---|
|
Return on equity(%)
|
4.12
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
22.21
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of InspireMD Inc (NSPR) was $0 Mln.
$0.10
(
